Detalles de la búsqueda
1.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Br J Cancer
; 127(5): 836-843, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35637412
2.
VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.
Breast Cancer Res Treat
; 176(3): 637-647, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31115844
3.
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
Int J Cancer
; 142(5): 1047-1055, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29047142
4.
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
Int J Cancer
; 140(8): 1918-1925, 2017 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28032641
5.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Lancet Oncol
; 17(10): 1426-1434, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27575024
6.
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Lancet Oncol
; 16(13): 1355-69, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26361971
7.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(10): 1065-75, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25088940
8.
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.
Lancet Gastroenterol Hepatol
; 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38870977
9.
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314).
Eur J Cancer
; 173: 297-306, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35970102
10.
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group.
Hemasphere
; 5(7): e600, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34179697
11.
Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
Eur J Cancer
; 101: 105-113, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30036739
12.
Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany.
J Geriatr Oncol
; 6(6): 462-9, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26341962
13.
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
J Clin Oncol
; 33(32): 3718-26, 2015 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26261259
14.
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eur Urol
; 68(5): 837-47, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25952317
15.
Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia.
Oncol Rep
; 10(4): 915-20, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-12792745
16.
Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study.
Oncol Res Treat
; 37(12): 748-55, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25531721
17.
Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.
J Thorac Oncol
; 9(11): 1704-8, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25436803
18.
Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study.
J Cancer Res Clin Oncol
; 139(12): 2047-56, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24072232
19.
Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors.
Oncologist
; 12(6): 748-55, 2007 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17602064
20.
Endobronchial mucosal metastases in breast cancer: a rare metastatic pattern.
Lancet Oncol
; 3(11): 702-3, 2002 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-12424074
Resultados
1 -
20
de 20
1
Próxima >
>>